Onkológia 3/2023

Systemic treatment of advanced pancreatic cancer and the role of nanoliposomal irinotecan in it

Pancreatic cancer is a serious malignant disease. Chemotherapy remains the main treatment option of advanced pancreatic cancer. FOLFIRINOX or nab-paclitaxel/ gemcitabine are recommended regimens in first-line treatment of metastatic disease. nal-IRI/5-FU/LV is considered one of the options of second-line treatment. Targeted- therapy is available in BRCA+ patients or within tumor-agnostic therapy. Immunotherapy appears to be effective only in MSI-h/dMMR patients. Unsatisfying outcomes of current systemic treatment of advanced pancreatic cancer warrant futher research on novel targeted theraphy and immunotherapy.

Keywords: pancreatic cancer, chemotherapy, irinotecan, 5-fluorouracil, oxaliplatin, nanoliposomal irinotecan